Scientific Sessions 2024  /  Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations  /  Discussant: VALOR-HCM
Logo

American Heart Association

  196
  0

Final ID:

Discussant: VALOR-HCM

  • Deswal, Anita  ( Univ. of Texas MD Anderson Cancer Center , Bellaire , Texas , United States )
  • Ho, Jennifer  ( Harvard Medical School , Newton , Massachusetts , United States )
  • Ho, Carolyn  ( Carolyn Ho , Brookline , Massachusetts , United States )
  • Day, Sharlene  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
    • Author Disclosures:
    Anita Deswal: DO have relevant financial relationships ; Consultant:Bayer (Any division):Active (exists now) | Jennifer Ho: DO have relevant financial relationships ; Individual Stocks/Stock Options:Pfizer:Active (exists now) | Carolyn Ho: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bristol Myers Squib:Active (exists now) ; Consultant:viz.ai:Active (exists now) ; Consultant:Lexicon:Active (exists now) ; Consultant:Tenaya:Active (exists now) ; Research Funding (PI or named investigator):Tenaya:Active (exists now) ; Consultant:Biomarin:Active (exists now) ; Research Funding (PI or named investigator):Biomarin:Active (exists now) ; Consultant:Cytokinetics:Active (exists now) ; Research Funding (PI or named investigator):Cytokinetics:Active (exists now) ; Consultant:Bristol Myers Squib:Active (exists now) | Sharlene Day: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

Monday, 11/18/2024 , 09:45AM - 11:00AM

Featured Science

More abstracts on this topic:
Discussant: ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis

Nativi-nicolau Jose

Mavacamten Treatment in Patients with Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results from VALOR-HCM Trial

Desai Milind, Nissen Steven

More abstracts from these authors:
Building Blocks: How To Build a Clinical Cardio-Oncology Program

Deswal Anita

The Rings of Power: HFrEF Quadruple Therapy and AF

Bozkurt Biykem, Deswal Anita, Dunlay Shannon

You have to be authorized to contact abstract author. Please, Login
Not Available